Histamine Responsiveness in McCune-Albright Syndrome
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
McCune-Albright syndrome (MAS) is a syndrome caused by a genetic mutation that causes a specific protein in the body called a G protein to be constantly active. Children with McCune-Albright syndrome classically have early puberty, areas of increased skin pigmentation, and bone lesions resulting from the constant activity of the specific protein involved.
Histamines are known to play a role in allergies and related allergic problems. The effects of histamines are controlled by the same G protein that is overly active in McCune-Albright syndrome. Thus, one could predict that patients with McCune-Albright may be at high risk for allergic problems. To date, no studies have documented any form of histamine excess or allergic difficulties in patients with McCune-Albright syndrome. However, the investigators have made the observation that a high percentage of their patients with MAS exhibit a range of allergic symptoms, from mild symptoms, to severe, life-threatening symptoms.
The purpose of this study is to demonstrate increased histamine response by using a histamine skin test in patients with MAS. If increased reactions to histamines can be documented in MAS patients when compared to controls, severe and potentially life threatening allergic reactions in children with MAS could be anticipated and avoided.
| Condition |
|---|
|
McCune-Albright Syndrome |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Primary Purpose: Screening Time Perspective: Cross-Sectional Time Perspective: Prospective |
| Official Title: | Histamine Responsiveness in Patients With McCune-Albright Syndrome |
Eligibility| Ages Eligible for Study: | up to 39 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Children with MAS ranging from toddlers to young adults.
- Diagnosis of MAS will be made on a clinical basis. Blood testing is not helpful in this condition, as bone marrow progenitor cells with the Gαs mutation display a survival disadvantage. All patients are mixed chimeras, as this mutation is lethal if it occurs in germline cells.
Patients who exhibit two or more of the following clinical findings fit the diagnosis of MAS:
- GnRH independent precocious puberty
- Polyostotic fibrous dysplasia
- Café-au-lait spots with coast of Maine borders and respect for the midline.
- Non-autoimmune hyperthyroidism.
- Ten controls will also be recruited from family members of patients with MAS with no known allergies. An additional control group of ten unrelated subjects, also with no known allergies, will be recruited from the Endocrine Clinic for comparison.
Exclusion Criteria:
- Any MAS patient or control who has not, or cannot, discontinue(d) any home regimens of antihistamines or glucocorticoids (including inhaled steroids) at least seven days prior to skin testing.
- Any MAS patient or control on tricyclic antidepressants within two weeks prior to skin testing.
Contacts and Locations| Contact: Angela L Turpin, MD | 816-234-3804 | aturpin@cmh.edu |
| Contact: Jill D Jacobson, MD | 816-234-3804 | jjacobson@cmh.edu |
| United States, Missouri | |
| Children's Mercy Hospitals and Clinics | Recruiting |
| Kansas City, Missouri, United States, 64108 | |
| Contact: Angela L Turpin, MD 816-234-3804 aturpin@cmh.edu | |
| Contact: Jill D Jacobson, MD 816-234-3804 jjacobson@cmh.edu | |
| Principal Investigator: | Angela L Turpin, MD | Children's Mercy Hospital Kansas City |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00318097 History of Changes |
| Other Study ID Numbers: | 03 11-116 |
| Study First Received: | April 24, 2006 |
| Last Updated: | May 1, 2006 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Children's Mercy Hospital Kansas City:
|
McCune Albright Syndrome Histamine regulation |
Additional relevant MeSH terms:
|
Fibrous Dysplasia, Polyostotic Fibrous Dysplasia of Bone Osteochondrodysplasias Bone Diseases, Developmental Bone Diseases Musculoskeletal Diseases Histamine |
Histamine phosphate Histamine Agonists Histamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 17, 2013